SEPTEMBER 1-2, 2020 GRAND HYATT, SÃO PAULO, BRAZIL

Presenting Companies

Alnylam Pharmaceuticals

Headquartered in Cambridge/MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines. Based on Nobel Prize-winning science, RNAi therapeutics represent a clinically validated approach for the treatment of diseases with high unmet need. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutic medicines, including four investigational medicines in late-stage development and one product commercialized in the US, European Union, Japan and Canada, with plans to expand to markets around the world. For more information visit www.alnylam.com.

 

Click here to go back to see other exhibitors.